Press release -

Sobi awarded Best Biotech Pipeline at World Orphan Drug Congress

Swedish Orphan Biovitrum AB (publ) (Sobi) has been awarded Best Biotech Pipeline at the World Orphan Drug Congress in Geneva. The award recognises the size and range of Sobi's orphan pipeline and also the mix across designation and authorisation phases within the portfolio. The judging panel also acknowledged Sobi's long-term future as well as the company's pioneering development approach and commitment to the rare disease and orphan drug space.

"We are truly honoured by this recognition", said Geoffrey McDonough, CEO at Sobi. "In our work to create a more hopeful future for patients with rare diseases we are also seeking new models for the development of orphan drugs."

Sobi was also recognized as part of the DevelopAKUre Consortium, which was awarded the Best European Industry - Patient Organisation Collaborationaward.

DevelopAKUre is a clinical trial programme for the drug nitisinone (Orfadin®), the first potential treatment for Alkaptonuria (AKU). It is made up of 13 hospitals, a pharmaceutical company, consultancies, universities, biotech companies and national AKU patient groups.

---

For more information - not for publication

Media relationsInvestor relations
Oskar Bosson, Head of CommunicationsJörgen Winroth, Vice President, Head of Investor Relations
T: +46 70 410 71 80T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135
oskar.bosson@sobi.comjorgen.winroth@sobi.com

Topics

  • Health, Health Care, Pharmaceuticals

Categories

  • sobi
  • best biotech pipeline
  • world orphan drug congress

About Sobi

Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Inflamma-tion and Genetic diseases, with three late stage biological development projects within Haemophilia and Neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion (€253 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More infor-mation is available at www.sobi.com.

 

Contacts

Charlotte af Klercker

Press contact Senior Communications Manager 0707-297327

Related media

Sobi awarded Best Biotech Pipeline at World Orphan Drug Congress
  • Sobi awarded Best Biotech Pipeline at World Orphan Drug Congress
  • License: Media Use
    The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
  • File format: .pdf
Download

Related content

Sobi receives EURORDIS Company Award 2014

Swedish Orphan Biovitrum AB (publ) (Sobi) was awarded the EURORDIS Company Award 2014 at the EURORDIS Black Pearl Gala Dinner on February 25. The award recognises pioneering companies developing treatments for rare diseases.

Sobi expands Haemophilia development portfolio — elects to include potentially longer-acting Haemophilia A candidate in collaboration agreement with Biogen Idec

Sobi has elected to add the preclinical rFVIIIFc-XTEN-vWF fusion molecule to the company’s collaboration with Biogen Idec. “Although at an early stage, the XTEN technology has the potential to further extend FVIII half-life and could one day potentially become a next-generation long-acting factor for people with haemophilia A.”, said Geoffrey McDonough, CEO and President Sobi.